Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

Claire Gillis appointed to newly created role of CEO of VMLY&R HEALTH

The company has also created an additional four new leadership roles

Meet The Lucid Group Talent Team

Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your...

Lucid Group Communications Limited

Celebrating the new UK rare diseases framework

Dice's take on the importance of the rare diseases framework

Dice Medical Communications

- PMLiVE

Pfizer and viral infection specialist ReViral agree on $525m deal

According to the deal, Pfizer will acquire ReViral for a total of up to $525m

- PMLiVE

Gavi, MedAccess and the Open Society Foundations partner to support COVAX

COVAX has delivered more than 1.4 billion COVID-19 vaccines to 145 countries and territories

- PMLiVE

Using consensus to drive clarity

By Derek Annan

Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal

A version of this article was previously published on Pharmaphorum.There is not a single industry that has been left untouched by COVID-19. While the effects of the pandemic have been devastating...

Impetus Digital

Data-Driven Approaches for Neurorecovery

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Impetus Digital

- PMLiVE

Living With Chronic Illness Podcast

The journey from the patient’s perspective

- PMLiVE

Sanofi’s asthma treatment approved by European Commission

Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation

- PMLiVE

EMA and ECDC publish advice on fourth doses of mRNA COVID-19 vaccines

The regulators have concluded that there is not enough supporting evidence for an immediate fourth dose

- PMLiVE

bluebird bio maintains its focus on gene therapy opportunities during structural changes

The company plans to reduce its workforce amid efforts to reduce its operating costs

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links